Artelo Biosciences
ARTL
7 hedge funds and large institutions have $111K invested in Artelo Biosciences in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.13% less ownership
Funds ownership: 0.23% → 0.09% (-0.13%)
13% less funds holding
Funds holding: 8 → 7 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less capital invested
Capital invested by funds: $338K → $111K (-$227K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$181K |
| 2 |
Two Sigma Advisers
New York
|
-$24.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Two Sigma Advisers
New York
| $63.2K | -$24.5K | -483 | -24% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $31.8K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $10K | +$7K | +138 | +152% |
|
|
4
UBS Group
Zurich,
Switzerland
| $5.52K | -$1.93K | -38 | -22% |
|
|
CFD
5
Creative Financial Designs
Kokomo,
Indiana
| $167 | – | – | – |
|
6
Morgan Stanley
New York
| $46 | – | – | – |
|
7
Wells Fargo
San Francisco,
California
| $42 | – | – | – |
|
|
8
Vanguard Group
Malvern,
Pennsylvania
| – | -$181K | -3,476 | Closed |
|
ARTL Hedge Fund Activity: Q1 2023 in Review
7 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2023, worth a combined $111K — down 67% from $338K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARTL and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $7K. The largest seller was Vanguard Group, exiting entirely with an estimated $181K sold.
- 7 institutional investors held Artelo Biosciences (ARTL) as of Q1 2023, down from 8 in Q4 2022.
- Funds reported $111K of Artelo Biosciences stock for Q1 2023, down 67% quarter-over-quarter.
- 0 funds opened new Artelo Biosciences positions in Q1 2023 and 1 closed out, a net change of -1 holder.
- The largest Artelo Biosciences buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $7K added.
- The largest Artelo Biosciences seller in Q1 2023 was Vanguard Group, an estimated $181K sold.
Based on aggregated 13F filings for Q1 2023.